Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Sep 1;16(9):2123-2130.
doi: 10.1080/21645515.2020.1757990. Epub 2020 May 19.

Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture

Mikhail F Vorovitch  1   2 , Karina G Grishina  1 , Viktor P Volok  3   4 , Liubov L Chernokhaeva  1 , Konstantin V Grishin  1 , Galina G Karganova  3   2 , Aidar A Ishmukhametov  5   2
Affiliations
Clinical Trial

Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture

Mikhail F Vorovitch et al. Hum Vaccin Immunother. .

Abstract

Approximately 10,000 cases of tick-borne encephalitis (TBE), a serious disease of the central nervous system caused by tick-borne encephalitis virus (TBEV), are registered worldwide every year. Vaccination against TBE remains the most essential measure of preventing the disease. Unlike available TBE vaccines, a new inactivated lyophilized candidate vaccine Evervac is produced in Vero continuous cell culture and its final formulation does not include aluminum-based adjuvants. To study the safety and immunogenicity of Evervac, healthy adults 18-60 y of age were immunized twice at 30-d intervals. The study was single-blind, randomized, comparative, controlled, and was conducted in TBE-endemic areas. The commercial lyophilized vaccine TBE-Moscow was used as a comparison treatment. The subjects were observed for incidence, severity, and duration of adverse reactions. It was shown that the severity of local and systemic reactions in the Evervac vaccine group was mild to moderate. There were no significant differences in the incidence of adverse reactions between the Evervac and TBE-Moscow vaccine groups. Immunization with Evervac produced a significant increase in geometric mean titer (GMT) of anti-TBEV antibodies in both initially seronegative and seropositive recipients. The seroconversion rate for the initially seronegative recipients was 69% (GMT = 1:214) after the first dose and reached 100% after the second dose. In these parameters, there were no significant differences between the study and control vaccine groups. Thus, the adjuvant-free Vero-based vaccine Evervac was well tolerated, had low reactogenicity, induced a pronounced immune response, and was overall non-inferior to the commercial adjuvanted TBE vaccine used as a control.

Keywords: Inactivated vaccine; flavivirus; immunogenicity; reactogenicity; tick-borne encephalitis; tick-borne encephalitis vaccine; vaccine safety.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Demina TV, Dzhioev YP, Verkhozina MM, Kozlova IV, Tkachev SE, Plyusnin A, Doroshchenko EK, Lisak OV, Zlobin VI.. Genotyping and characterization of the geographical distribution of tick-borne encephalitis virus variants with a set of molecular probes. J Med Virol. 2010;82(6):965–76. doi:10.1002/jmv.21765. PMID: 20419810. - DOI - PubMed
    1. Ruzek D, Avšič Županc T, Borde J, Chrdle A, Eyer L, Karganova G, Kholodilov I, Knap N, Kozlovskaya L, Matveev A, et al. Tick-borne encephalitis in Europe and Russia: review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res. 2019;164:23–51. doi:10.1016/j.antiviral.2019.01.014. PMID: 30710567. - DOI - PubMed
    1. Vorovitch MF, Maikova GB, Chernokhaeva LL, Romanenko VV, Karganova GG, Ishmukhametov AA.. Comparison of the immunogenicity and safety of two pediatric TBE vaccines based on the Far Eastern and European virus subtypes. Adv Virol. 2019;24:5323428. doi:10.1155/2019/5323428. PMID: 31933642. - DOI - PMC - PubMed
    1. Domnich A, Panatto D, Arbuzova EK, Signori A, Avio U, Gasparini R, Amicizia D. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on European subtype: systematic review and meta-analysis. Hum Vaccine Immunoter. 2014;10(10):2818–33. doi:10.4161/hv.29984. PMID: 25483679. - DOI - PMC - PubMed
    1. Morozova OV, Bakhvalova VN, Potapova OF, Grishechkin AE, Isaeva EI, Aldarov KV, Klinov DV, Vorovich MF. Evaluation of immune response and protective effect of four vaccines against the tick-borne encephalitis virus. Vaccine. 2014;32(25):3101–06. doi:10.1016/j.vaccine.2014.02.046. - DOI - PubMed

Publication types